Stockscreener 앱 받기
20.22
6.52%
-1.41
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
(NVCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Nuvectis Pharma Earns Breakthrough Therapy Status in China for Brain Cancer Treatment NXP200 - Kalkine Media
Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead - benzinga.com
Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation In China, And It's Not Even Their Lead Asset - Mena FN
Nuvectis’ NXP200 receives breakthrough therapy status in China By Investing.com - Investing.com Canada
Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma - marketscreener.com
Nuvectis’ NXP200 receives breakthrough therapy status in China - Investing.com
A brain tumor drug gets China’s breakthrough designation. Nuvectis is advancing NXP200 toward a U.S. filing in Q4. - Stock Titan
Nuvectis Pharma (NVCT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Nuvectis Pharma (NVCT) Climbs 2.90% to $22.00 as Buyers Approach ResistanceExtension Target - siam.in
Nuvectis Pharma: Haisco Licensing Deal Revitalizes BiotechBut No Rush To Invest Today - Seeking Alpha
Nuvectis Pharma at H.C. Wainwright conference: pipeline and cash stand out - Investing.com Canada
NVCT: Strong clinical progress and financial position drive near-term catalysts in precision medicine - TradingView
Nuvectis at Cantor healthcare conference: betting on factor B By Investing.com - Investing.com Canada
NVCT: NXP100's once-daily dosing and strong efficacy position it to disrupt the PNH market - TradingView
Nuvectis at Cantor healthcare conference: betting on factor B - investing.com
NVCT: NXP100's once-daily dosing and strong PNH data position it for pivotal U.S. trials and expansion - tradingview.com
Nuvectis Pharma, Inc. (NVCT) Stock Price & News - Syfe
(NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Nuvectis Pharma To Participate in Upcoming Investor Conferences - Investing News Network
Nuvectis Pharma plans two September talks, both available online - Stock Titan
Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT) - Benzinga
Nuvectis Pharma (NVCT) Rises 3.75% to $23.93, Pressing Against Key ResistanceHigh Volume Stocks - vinanet.vn
Lucid Capital Markets initiates Nuvectis Pharma stock with buy rating By Investing.com - Investing.com UK
Nuvectis Pharma Inc (NVCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvectis Pharma, Inc. SEC Filing (Aug 31, 2026) - Stock Titan
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - qz.com
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - easternprogress.com
Nuvectis Pharma Launches New $200 Million ATM Program - TipRanks
Nuvectis Pharma (Nasdaq: NVCT) sets at-the-market stock sales capacity - Stock Titan
Nuvectis Pharma (NASDAQ: NVCT) sets at-the-market share sales via Jefferies - Stock Titan
Nuvectis (NVCT): Moves 0.26% Down to $23.29; Boundary Watch: $22.13 and $24.45 Define the Nearby Reference Levels in the Latest SessionProfit Surge Picks - vinanet.vn
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate - Sahm
Nuvectis (NVCT) Quarterly Scorecard: EPS Misses Its Estimate at the Close; Trading Response: Shares Finish 0.09% Higher on the DayManagement Guidance Update - dars.gov.et
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why - Yahoo Finance
Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% HigherWhat's Next? - MarketBeat
Nuvectis Pharma (NVCT) Slips 1.4% to $18.96 as Shares Approach Key Support LevelALMA Signal - vinanet.vn
Behavioral Patterns of NVCT and Institutional Flows - Stock Traders Daily
NVCT Q2 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline ProgressesInvestor Earnings Call - vinanet.vn
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap UpWhat's Next? - MarketBeat
NVCT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued R&D InvestmentPre-Earnings Setup - vinanet.vn
NVCT Q2 2026 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage Investment PhaseShort-Term Outlook - dars.gov.et
Certain Stock Options of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Certain Common Stock of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Nuvectis Pharma (NVCT) Holds Near $18.88 as Shares Consolidate Between Support and ResistanceWave Truncation - dars.gov.et
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline Amid Ongoing Clinical DevelopmentPerformance Review - careplusvn.com
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market Wi - The National Law Review
Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next - TipRanks
Soleus group (NVCT) discloses 1.65M-share, 5.1% Nuvectis Pharma stake - Stock Titan
HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma - MarketBeat
(NVCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Nuvectis Pharma’s Heavy Reliance on Haisco Poses Major Operational and Geopolitical Risks - TipRanks
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss - MarketBeat
Nuvectis Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nuvectis Pharma, Inc. 2Q 2026: Net loss $(7.02)M, EPS $(0.30) — 10-Q Summary - TradingView
NVCT: Q2 2026 net loss widened to $7.0M; $106.3M raised in July extends cash runway for clinical development - TradingView
Nuvectis Pharma (NASDAQ: NVCT) boosts cash with $115M stock sale and new drug licenses - Stock Titan
Nuvectis Reports $7.0 Million Q2 Net Loss After Pipeline Deals - Quiver Quantitative
NVCT: Secured $115M financing, advanced late-stage pipeline, and reported higher R&D-driven net loss - tradingview.com
Nuvectis Pharma Reports Q2 2026 Results, Highlights In-Licensing of Ciprocopan and NXP200 and $115 Million Follow-On Offering - Quiver Quantitative
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
3.06%
2.55%
자본화:
|
볼륨(24시간):